These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 23590356)

  • 1. Pharmacokinetics and pharmacodynamics of sunitinib for the treatment of advanced pancreatic neuroendocrine tumors.
    Bisht S; Feldmann G; Brossart P
    Expert Opin Drug Metab Toxicol; 2013 Jun; 9(6):777-88. PubMed ID: 23590356
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sunitinib in pancreatic neuroendocrine tumors.
    Raymond E; Hammel P; Dreyer C; Maatescu C; Hentic O; Ruszniewski P; Faivre S
    Target Oncol; 2012 Jun; 7(2):117-25. PubMed ID: 22661319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sunitinib malate for the treatment of pancreas malignancies--where does it fit?
    Mankal P; O'Reilly E
    Expert Opin Pharmacother; 2013 Apr; 14(6):783-92. PubMed ID: 23458511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sunitinib for advanced pancreatic neuroendocrine tumors.
    Hubner RA; Valle JW
    Expert Rev Anticancer Ther; 2011 Dec; 11(12):1817-27. PubMed ID: 22117148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiangiogenic Therapy in Pancreatic Neuroendocrine Tumors.
    Capozzi M; VON Arx C; DE Divitiis C; Ottaiano A; Tatangelo F; Romano GM; Tafuto S;
    Anticancer Res; 2016 Oct; 36(10):5025-5030. PubMed ID: 27798861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Benefits from pharmacological and pharmacokinetic properties of sunitinib for clinical development.
    Sablin MP; Dreyer C; Colichi C; Bouattour M; Delbaldo C; Faivre S; Raymond E
    Expert Opin Drug Metab Toxicol; 2010 Aug; 6(8):1005-15. PubMed ID: 20636223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sunitinib: in advanced, well differentiated pancreatic neuroendocrine tumors.
    Deeks ED; Raymond E
    BioDrugs; 2011 Oct; 25(5):307-16. PubMed ID: 21942915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.
    Raymond E; Dahan L; Raoul JL; Bang YJ; Borbath I; Lombard-Bohas C; Valle J; Metrakos P; Smith D; Vinik A; Chen JS; Hörsch D; Hammel P; Wiedenmann B; Van Cutsem E; Patyna S; Lu DR; Blanckmeister C; Chao R; Ruszniewski P
    N Engl J Med; 2011 Feb; 364(6):501-13. PubMed ID: 21306237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of sunitinib in Japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumor.
    Ito T; Okusaka T; Nishida T; Yamao K; Igarashi H; Morizane C; Kondo S; Mizuno N; Hara K; Sawaki A; Hashigaki S; Kimura N; Murakami M; Ohki E; Chao RC; Imamura M
    Invest New Drugs; 2013 Oct; 31(5):1265-74. PubMed ID: 23269537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imaging response in neuroendocrine tumors treated with targeted therapies: the experience of sunitinib.
    Faivre S; Ronot M; Dreyer C; Serrate C; Hentic O; Bouattour M; Bruno O; Couvelard A; Vilgrain V; Raymond E
    Target Oncol; 2012 Jun; 7(2):127-33. PubMed ID: 22585430
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sunitinib (Sutent): a novel agent for the treatment of metastatic renal cell carcinoma.
    Chouhan JD; Zamarripa DE; Lai PH; Oramasionwu CU; Grabinski JL
    J Oncol Pharm Pract; 2007 Mar; 13(1):5-15. PubMed ID: 17621562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Everolimus for the treatment of pancreatic neuroendocrine tumors.
    Feldmann G; Bisht S; Schütte U; Haarmann J; Brossart P
    Expert Opin Pharmacother; 2012 Oct; 13(14):2073-84. PubMed ID: 22873789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imaging guided trials of the angiogenesis inhibitor sunitinib in mouse models predict efficacy in pancreatic neuroendocrine but not ductal carcinoma.
    Olson P; Chu GC; Perry SR; Nolan-Stevaux O; Hanahan D
    Proc Natl Acad Sci U S A; 2011 Dec; 108(49):E1275-84. PubMed ID: 22084065
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of everolimus and sunitinib in patients with gastroenteropancreatic neuroendocrine tumor.
    Yoo C; Cho H; Song MJ; Hong SM; Kim KP; Chang HM; Chae H; Kim TW; Hong YS; Ryu MH; Kang YK; Kim SC; Ryoo BY
    Cancer Chemother Pharmacol; 2017 Jan; 79(1):139-146. PubMed ID: 27942928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of everolimus vs sunitinib in treating patients with advanced, progressive pancreatic neuroendocrine tumors in the United States.
    Casciano R; Chulikavit M; Perrin A; Liu Z; Wang X; Garrison LP
    J Med Econ; 2012; 15 Suppl 1():55-64. PubMed ID: 22881362
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient-Reported Outcomes and Quality of Life with Sunitinib Versus Placebo for Pancreatic Neuroendocrine Tumors: Results From an International Phase III Trial.
    Vinik A; Bottomley A; Korytowsky B; Bang YJ; Raoul JL; Valle JW; Metrakos P; Hörsch D; Mundayat R; Reisman A; Wang Z; Chao RC; Raymond E
    Target Oncol; 2016 Dec; 11(6):815-824. PubMed ID: 27924459
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Practical management of sunitinib toxicities in the treatment of pancreatic neuroendocrine tumors.
    Valle JW; Faivre S; Hubner RA; Grande E; Raymond E
    Cancer Treat Rev; 2014 Dec; 40(10):1230-8. PubMed ID: 25283354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sunitinib shrinks NET-G3 pancreatic neuroendocrine neoplasms.
    Mizuno Y; Kudo A; Akashi T; Akahoshi K; Ogura T; Ogawa K; Ono H; Mitsunori Y; Ban D; Tanaka S; Tateishi U; Tanabe M
    J Cancer Res Clin Oncol; 2018 Jun; 144(6):1155-1163. PubMed ID: 29602973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activity of sunitinib in patients with advanced neuroendocrine tumors.
    Kulke MH; Lenz HJ; Meropol NJ; Posey J; Ryan DP; Picus J; Bergsland E; Stuart K; Tye L; Huang X; Li JZ; Baum CM; Fuchs CS
    J Clin Oncol; 2008 Jul; 26(20):3403-10. PubMed ID: 18612155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sunitinib: a newly approved small-molecule inhibitor of angiogenesis.
    Cabebe E; Wakelee H
    Drugs Today (Barc); 2006 Jun; 42(6):387-98. PubMed ID: 16845442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.